UK life sciences-focused firm Abingworth Management is reportedly nearing a final close for its sixth fund, which has been oversubscribed.
Abingworth Bioventures VI is set to close on £225m, ahead of its £200m initial target, said Dow Jones, citing a person close to the effort.
Back in October AltAssets reported that Abingworth had raised £205.5m from 31 LPs.
Abingworth provides venture and growth capital and invests in publicly listed companies in the life sciences and healthcare sectors, making minority and majority deals valued at between $20m and $80m.
The firm has invested in more than 100 life sciences companies, third of which have been acquired or have gone public.
Abingworth’s investees include Menlo Park-based startup Personalis, which provides medical exome and genome sequencing and interpretation services.
Copyright © 2014 AltAssets